Discovery of Tumor, Treatment Response, and Systems-based EVP Signatures

肿瘤、治疗反应和基于系统的 EVP 特征的发现

• 批准号: 10702580
• 负责人: Jennifer Jones
• 金额: $ 76.76万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702580
• 关键词: Blood Vessels; CCR; Cells; Cessation of life; Clinical; Clinical Protocols; Disease; Disseminated Malignant Neoplasm; Elements; Goals; Immune; Immune response; Immunosuppression; Laboratories; Laboratory Research; Malignant Neoplasms; Medical Oncology; Patient Care; Patient Monitoring; Patients; Protocols documentation; Quality of life; Radiation; Radiation Oncologist; Radiation Oncology; Radiation therapy; Research; Role; Sampling; Stromal Cells; Stromal Neoplasm; Study Section; Surgical Oncology; System; Translational Research; Tumor Markers; United States National Institutes of Health; Unresectable; Work; base; clinical practice; cohesion; curative treatments; design; extracellular vesicles; immune activation; improved; improved outcome; irradiation; liquid biopsy; nanobiology; neoplastic cell; particle; patient population; phosphatidylserine receptor; response to injury; tissue injury; tool; translational goal; translational research program; treatment response; tumor; tumor progression

As a practicing radiation oncologist, seeking to integrate my laboratory and clinical efforts into a cohesive translational research program, I have focused my clinical practice on the care of patients with metastatic cancers, for whom radiation may be beneficial. In the past year, I created the Treatment of Extra-cranial Advanced Malignancies (TEAM) group in the NCI Radiation Oncology Branch, and we are developing protocols designed to improve the assessment and treatment of patients with advanced malignancies. A major focus of my work with the TEAM group is liquid biopsies, and a major research aim currently is to determine what liquid biopsy or biofluid EVP profiles correlate with responses to treatment. The translational research efforts of this project are following a two-pronged approach: 1) collaborating with medical and surgical oncology colleagues at NIH to investigate EVPs as biomarkers for tumor status as part of those collaborators' existing protocols, and 2) developing new clinical protocols to capture information and samples from this patient population in a more cohesive and informative manner. Both of these approaches are supported by and provide support to the CCR's clinical translational mission and the basic scientific work ongoing in the Translational Nanobiology Section for the study of EVP repertoires.

作为一名执业放射肿瘤学家，寻求整合我的实验室和临床 努力成为一个有凝聚力的转化研究计划，我把我的临床实践集中在 转移性癌症患者的护理，放射治疗可能对他们有益。在 去年，我创建了颅外晚期恶性肿瘤（TEAM）治疗组， NCI放射肿瘤学分支，我们正在制定旨在改善 评估和治疗晚期恶性肿瘤患者。我工作的一个主要重点是 TEAM组是液体活检，目前的主要研究目标是确定 液体活组织检查或生物流体EVP谱与对治疗的反应相关。的 本项目的转化研究工作遵循两种方法：1） 与NIH的内科和外科肿瘤学同事合作， 肿瘤状态的生物标志物作为这些合作者现有方案的一部分，以及2） 开发新的临床方案以获取该患者的信息和样本 以更有凝聚力和信息量的方式进行人口普查。支持这两种方法 并为CCR的临床转化使命和基础科学 翻译纳米生物学部分正在进行的EVP研究工作 保留曲目